Welcome to our dedicated page for Icu Medical SEC filings (Ticker: ICUI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ICU Medical, Inc. (Nasdaq: ICUI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, together with AI-powered tools to help interpret them. ICU Medical is a medical technology company headquartered in San Clemente, California, and describes itself as a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings.
ICU Medical files periodic and current reports with the U.S. Securities and Exchange Commission, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. For example, the company has filed Form 8-K reports to furnish press releases announcing its quarterly financial results. These filings provide detail on total revenues, cost of goods sold, gross profit, operating expenses, product line revenues for Consumables, Infusion Systems and Vital Care, net income or loss, cash flows and non-GAAP measures such as adjusted EBITDA and adjusted diluted earnings per share.
On Stock Titan, AI-generated summaries can highlight key elements of ICU Medical’s filings, helping users quickly understand disclosures related to product line performance, restructuring and integration expenses, contract manufacturing, joint ventures such as Otsuka ICU Medical LLC, and the risk factors the company describes in its Form 10-K and subsequent filings. Real-time updates from EDGAR ensure that new ICUI filings, including Forms 10-K, 10-Q, 8-K and other relevant documents, are added as they become available.
The filings page can also be used to review information that underlies the company’s press releases, such as the 8-K items that reference earnings announcements. By combining official SEC documents with AI explanations, this resource helps investors and analysts navigate ICU Medical’s financial reporting, segment disclosures and regulatory communications without having to manually parse every line of each filing.
ICU Medical Chief Operating Officer Christian B. Voigtlander reported compensation-related share activity tied to performance awards. He exercised performance-based restricted stock units and restricted stock units that settled into 14,648 shares of Common Stock, with no purchase or exercise price.
These units were granted on 3/15/2023 and, after the Compensation Committee certified results on 2/11/26, the performance-based awards were earned at 117% of target. To cover tax obligations, 8,096 shares were withheld at $125.85 per share, leaving a net increase of 6,552 shares. Following these transactions, Voigtlander directly owns 46,306 shares of Common Stock.
ICU Medical Inc. executive Daniel Woolson, VP and GM-Infusion Capital, exercised performance-based restricted stock units into common stock. He converted 2,924 performance shares into 2,924 shares of common stock, then had 1,295 of those shares withheld to cover tax obligations at
ICU Medical Inc. Chief Information Officer Ben Sousa reported compensation-related equity activity involving Restricted Stock Units. On
ICU Medical Inc. VP and General Counsel Virginia Ruth Sanzone reported compensation-related equity activity. On March 15, 2026, she settled performance-based restricted stock units and restricted stock units that converted into 7,324 shares of Common Stock.
To cover tax obligations, 4,047 shares were withheld at $125.85 per share, resulting in a net addition of 3,277 shares. Following these transactions, she directly holds 21,907 shares of ICU Medical common stock. The PRSUs, granted on March 15, 2023, were earned at 117% of target after performance certification.
ICU Medical (ICUI) Chairman and CEO Vivek Jain reported equity award activity and related tax withholding. On
ICU Medical Chief Financial Officer Brian Michael Bonnell exercised stock awards and settled related taxes in shares. He exercised performance-based restricted stock units and restricted stock units, acquiring 14,648 shares of common stock with no cash exercise price. To cover tax liabilities, 7,595 shares were withheld at $125.85 per share, a non-market disposition. After these compensation-related transactions, he directly owns 71,750 shares of ICU Medical common stock.
ICU Medical Chief Financial Officer Brian Michael Bonnell reported equity award activity involving performance-based and time-based stock units. On March 8, 2026, performance stock units granted on March 8, 2024 were certified at 250% of target, resulting in the acquisition of 71,757 shares of common stock, with no exercise price.
On the same date, 39,667 shares of common stock were disposed of at $132.00 per share to cover tax obligations through share withholding, leaving 64,697 shares directly owned afterward. On March 7, 2026, additional equity awards were settled, including 3,522 shares acquired via derivative exercises and 1,263 shares withheld for taxes, resulting in 32,607 directly owned shares after that date.
ICU Medical Chairman and CEO Vivek Jain reported multiple equity award transactions. On March 8, 2026, he exercised 107,635 performance shares at $0.00 per share, acquiring the same number of common shares, which were earned at 250% of target PRSU performance after Compensation Committee certification.
That same day, 59,500 common shares were disposed of at $132.00 per share to satisfy tax obligations through share withholding, not an open-market sale. On March 7, 2026, he exercised awards covering 5,282 shares twice (derivative and non-derivative reporting), and 2,919 shares were withheld for taxes. Following these events, he also reported 152,339 common shares held indirectly through a trust.
ICU Medical Chief Information Officer Ben Sousa reported multiple equity award transactions. On 3/7/26 and 3/8/26, he acquired common stock through the exercise or settlement of Restricted Stock Units and performance-based Restricted Stock Units, including 7,177 performance shares earned at 250% of target following Compensation Committee certification.
On both dates, some common shares were disposed of in transactions coded “F” at a price of $132 per share, representing shares withheld to satisfy tax obligations rather than open-market sales. After these transactions, Sousa directly owned 4,744 shares of ICU Medical common stock.
ICU Medical (ICUI) VP and General Counsel Virginia Ruth Sanzone reported equity award activity involving restricted and performance-based stock units. On March 7 and 8, 2026, she acquired multiple blocks of Common Stock through exercises or conversions of derivative awards, including 23,917 Performance Shares and several smaller tranches.
The filing also shows dispositions of Common Stock coded as tax-withholding events, with 13,221 shares and 1,762 shares delivered at a price of